Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07610525 · ClinicalTrials.gov registry record · Phase 2
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07610525: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07610525 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07610525, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.
Interventions
- DRUG Pembrolizumab
- DRUG Paclitaxel + Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-11-05 |
| Est. Completion | 2031-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07610525
The ClinicalTrials.gov registry entry for NCT07610525 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07610525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07610525 about?
NCT07610525 is a clinical study titled "Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial". To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.
What is the current status of trial NCT07610525?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-11-05. Estimated completion is 2031-01-15.
What interventions are being tested in trial NCT07610525?
The interventions under investigation include: Pembrolizumab (DRUG), Paclitaxel + Carboplatin (DRUG).
Who is sponsoring clinical trial NCT07610525?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.